Vitamin E Dosing Study

Phase 2 Completed NCT04801849

Condition	Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Phase	Phase 2
Sponsor	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Status	Completed
Enrollment	200 participants
Interventions	Vitamin E
Start date	Aug 5, 2022
Completion date	Mar 4, 2025
Results posted	Mar 25, 2026

Summary

This is a multicenter, randomized, double masked, placebo-controlled, parallel treatment groups dosing trial of Vitamin E in adult nonalcoholic fatty liver disease (NAFLD).

Relative Change in Alanine Aminotransferase (ALT) From Baseline to 24 Weeks

Baseline to 24 weeks (end of treatment) · % change

Vitamin E, 200 IU	-38.4 ± 31.9 % change
Vitamin E, 400 IU	-36.3 ± 31.1 % change
Vitamin E, 800 IU	-36.4 ± 43.1 % change
Placebo	-12.2 ± 33.4 % change

p-value	<0.0001

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский